Radiation Oncology/Hodgkin/Lymphocyte predominant

Hodgkin's Lymphoma: Lymphocyte Predominant Lymphocyte-predominant has a different natural history (especially stages I-II) and response to therapy than classical HL. Chemo is not indicated in most early stage cases, and standard is IFRT. LP has best prognosis of HL subtypes, but late recurrences common and long-term followup necessary. NCCN Guidelines Stage I-IIA: IFRT or regional RT Stage I-IIB w/ B sx's: chemotherapy followed by IFRT Stage III-IVA: chemotherapy +/- RT –OR— observation (cat 2B) –OR— local RT (palliation only) or rituximab Stage III-IVB: chemotherapy +/- RT or rituximab +/- chemo +/- RT Studies Germany, 1999 10071266 — "Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease." Diehl V; J Clin Oncol. 1999 Mar;17(3):776-83. GHSG, 2005 16093276 — "Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG)." Nogova L; Ann Oncol. 2005 Oct;16(10):1683-7. GHSG, 2008 18086799 — "Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group." Nogova L; J Clin Oncol